Altimmune to Announce First Quarter 2020 Financial Results on May 14

May 8, 2020 at 7:00 AM EDT

GAITHERSBURG, Md., May 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020.

Conference Call Details

Date:	Thursday, May 14
Time:	8:30 am Eastern Time
Domestic:	855-327-6837
International:	631-891-4304
Conference ID:	10009533
Webcast:	http://public.viavid.com/index.php?id=139687

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ an AdCOVID™). For more information on Altimmune, please visit www.altimmune.com.

Contacts:

Will Brown	Ashley R. Robinson
Chief Financial Officer	LifeSci Advisors, LLC
Phone: 240-654-1450	617-430-7577
wbrown@altimmune.com	arr@lifesciadvisors.com

Source: Altimmune, Inc.